poisar

Stock

AC Immune SA ACIU

$2.50-2.92%

Overview

ACIU market data

Price History

ACIU price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.70
Diluted earnings per share over the trailing twelve months.
Beta
1.55
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,788.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.03 – $4.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $267.2M · P/B 5.62 · P/S 58.60.

Company News

7 captured
AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026Benzinga · Aug 11, 2026, 11:04 AM
BTIG Reiterates Buy on AC Immune, Maintains $8 Price TargetBenzinga · Aug 5, 2026, 8:06 PM
AC Immune Announces Three Presentations At The Alzheimer's Association International Conference, July 12-15Benzinga · Jul 7, 2026, 11:15 AM
AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three CohortsBenzinga · Jun 30, 2026, 11:20 AM
AC Immune Gets $4M Grant for Parkinson's Trial ExtensionBenzinga · Jun 11, 2026, 11:05 AM
AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral SclerosisBenzinga · May 22, 2026, 11:15 AM
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSGlobenewswire Inc · May 22, 2026, 11:15 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock